BCR-ABL inhibitor-resistant KCL-22 single clone #1
BCR-ABL inhibitor-resistant KCL-22 single clone #4
BCR-ABL inhibitor-resistant KCL-22 single clone #2
BCR-ABL inhibitor-resistant KCL-22 single clone #3

treatment: ClonTracer-barcoded KCL-22 cell population was treated with 0.1% DMSO for 7 days.
resistant to: Vehicle control - Treated with 0.1% DMSO
treatment: ClonTracer-barcoded KCL-22 cell population was treated with 2.5 µM imatinib for 27 days to acquire imatinib-resistant cell population.
treatment: ClonTracer-barcoded KCL-22 cell population was treated with 0.3 µM nilotinib for 27 days to acquire nilotinib-resistant cell population.
treatment: ClonTracer-barcoded KCL-22 cell population was treated with 2.5 µM GNF-2 for 21 days to acquire GNF-2-resistant cell population.
treatment: Single clone was isolated from 2.5 µM GNF-2-resistant ClonTracer-barcoded KCL-22 subpopulation and expanded. This clone is never exposed to catalytic BCR-ABL inhibitors.
resistant to: 2.5 µM imatinib/0.3 µM nilotinib/2.5 µM GNF-2
treatment: Single clone was isolated from 2.5 µM imatinib-resistant ClonTracer-barcoded KCL-22 subpopulation and expanded. This clone is never exposed to allosteric BCR-ABL inhibitors.
resistant to: 2.5 µM imatinib/0.3 µM nilotinib